GlassScriptPhysician profile
Emily A Kerns
NPI 1942845375
$2,914.47
in general payments reported to CMS, 2019-2025
41 companies · $733 in 2025
The $733 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $600 · 2022: $430 · 2023: $614 · 2024: $538 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Entertainment: $12.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.41 |
| Entertainment | $12.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.64 | 2021-2025 | |
| Novo Nordisk INC | $253.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $230.66 | 2021-2025 | Rexulti |
| Amgen INC. | $204.84 | 2023-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $189.54 | 2021-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $151.57 | 2021-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $129.11 | 2021-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $97.86 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $76.25 | 2023 | Veozah |
| Abbott Laboratories | $76.14 | 2022-2024 | Proclaim, Freestyle Libre 3 |
| Acadia Pharmaceuticals INC | $75.55 | 2022-2024 | Nuplazid |
| Glaxosmithkline, LLC. | $70.75 | 2021-2023 | Arexvy, Shingrix |
| Viatris Specialty LLC | $68.44 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $59.44 | 2021-2025 | Verquvo, Steglatro, Belsomra |
| Novartis Pharmaceuticals Corporation | $58.73 | 2023-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Kerns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.